Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.

On Friday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $2.6 which represents a slight increase of $0.05 or 1.96% from the prior close of $2.55. The stock opened at $2.55 and ...

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

Alector, Inc. (NASDAQ:ALEC – Free Report) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Alector in a ...

Alector (NASDAQ:ALEC – Free Report) had its price target reduced by HC Wainwright from $35.00 to $7.00 in a report published on Friday, MarketBeat.com reports. They currently have a buy rating on the ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today.Don't Miss our Black ...